Amicus Therapeutics (FOLD) discloses a preclinical Chaperone-Advanced Replacement Therapy...

|About: Amicus Therapeutics, Inc. (FOLD)|By:, SA News Editor

Amicus Therapeutics (FOLD) discloses a preclinical Chaperone-Advanced Replacement Therapy program for the lysosomal storage disease Mucopolysaccharidosis Type I. The company says it has received a grant of $250K from a "private U.S.-based donor" in connection with its development of a treatment. (PR)